JP2015537008A5 - - Google Patents

Download PDF

Info

Publication number
JP2015537008A5
JP2015537008A5 JP2015542121A JP2015542121A JP2015537008A5 JP 2015537008 A5 JP2015537008 A5 JP 2015537008A5 JP 2015542121 A JP2015542121 A JP 2015542121A JP 2015542121 A JP2015542121 A JP 2015542121A JP 2015537008 A5 JP2015537008 A5 JP 2015537008A5
Authority
JP
Japan
Prior art keywords
optionally substituted
membered monocyclic
alkyl
phenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015542121A
Other languages
English (en)
Japanese (ja)
Other versions
JP6377068B2 (ja
JP2015537008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2013/000957 external-priority patent/WO2014075168A1/en
Publication of JP2015537008A publication Critical patent/JP2015537008A/ja
Publication of JP2015537008A5 publication Critical patent/JP2015537008A5/ja
Application granted granted Critical
Publication of JP6377068B2 publication Critical patent/JP6377068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015542121A 2012-11-16 2013-11-15 ピラゾロピリミジン化合物 Active JP6377068B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261727581P 2012-11-16 2012-11-16
US61/727,581 2012-11-16
US201361808152P 2013-04-03 2013-04-03
US61/808,152 2013-04-03
PCT/CA2013/000957 WO2014075168A1 (en) 2012-11-16 2013-11-15 Pyrazolopyrimidine compounds

Publications (3)

Publication Number Publication Date
JP2015537008A JP2015537008A (ja) 2015-12-24
JP2015537008A5 true JP2015537008A5 (enExample) 2017-02-09
JP6377068B2 JP6377068B2 (ja) 2018-08-22

Family

ID=50730425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542121A Active JP6377068B2 (ja) 2012-11-16 2013-11-15 ピラゾロピリミジン化合物

Country Status (24)

Country Link
US (9) US9573954B2 (enExample)
EP (2) EP2920181B1 (enExample)
JP (1) JP6377068B2 (enExample)
CN (1) CN105793261B (enExample)
AU (1) AU2013344716B2 (enExample)
BR (1) BR112016010080B1 (enExample)
CA (1) CA2889919C (enExample)
CY (1) CY1120480T1 (enExample)
DK (1) DK3068786T3 (enExample)
ES (1) ES2686097T3 (enExample)
HR (1) HRP20181041T1 (enExample)
HU (1) HUE039351T2 (enExample)
IL (1) IL245187B (enExample)
LT (1) LT3068786T (enExample)
ME (1) ME03093B (enExample)
MX (1) MX373713B (enExample)
NZ (1) NZ707432A (enExample)
PL (1) PL3068786T3 (enExample)
PT (1) PT3068786T (enExample)
RS (1) RS57481B1 (enExample)
SG (1) SG11201603102TA (enExample)
SI (1) SI3068786T1 (enExample)
TW (1) TWI679201B (enExample)
WO (2) WO2014075168A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
EP3191095A2 (en) * 2014-09-08 2017-07-19 Dana Farber Cancer Institute, Inc. Methods of treating cancer comprising administering a ppar-gamma agonist
WO2016073891A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
KR102662215B1 (ko) 2014-11-06 2024-05-02 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
CA2989722C (en) * 2015-06-24 2023-09-19 Jacob Westman Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
JP7034935B2 (ja) 2016-04-06 2022-03-14 リソソーマル・セラピューティクス・インコーポレイテッド ピロロ[1,2-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP6961675B2 (ja) * 2016-07-18 2021-11-05 ユニバーシティー ヘルス ネットワーク Ttk阻害剤の固体形態
MY205416A (en) 2017-07-28 2024-10-21 Takeda Pharmaceuticals Co Tyk2 inhibitors and uses thereof
WO2019023786A1 (en) * 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
CN112334135A (zh) * 2018-05-23 2021-02-05 大学健康网络 治疗特征在于纺锤体和着丝粒相关复合物亚基3(ska3)基因的高表达水平的癌症的方法
SG11202104229WA (en) 2018-10-30 2021-05-28 Kronos Bio Inc Compounds, compositions, and methods for modulating cdk9 activity
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CN113773324B (zh) * 2021-09-07 2022-07-26 武汉九州钰民医药科技有限公司 抗肿瘤药cfi-402257的合成制备工艺
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
JPH04156452A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
JPH04156453A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
WO2001023388A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
WO2003076441A1 (en) 2002-03-07 2003-09-18 Smithkline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
CN100343255C (zh) 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5-a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
PL382706A1 (pl) 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7078525B2 (en) 2002-09-04 2006-07-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497440C (en) 2002-09-04 2011-03-22 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
US7569571B2 (en) 2003-12-23 2009-08-04 Novartis Ag Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators
TW200536536A (en) 2004-02-25 2005-11-16 Schering Corp Pyrazolotriazines as kinase inhibitors
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0616985B1 (pt) 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
US7750007B2 (en) 2006-11-06 2010-07-06 Supergen, Inc. Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
JP2010534206A (ja) * 2007-07-20 2010-11-04 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ[1,5−a]ピリミジン誘導体
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2011090935A1 (en) 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN103038235B (zh) 2010-06-01 2015-07-29 拜耳知识产权有限责任公司 取代的咪唑并吡嗪
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
US20120149708A1 (en) 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
JP5878171B2 (ja) 2010-06-24 2016-03-08 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス剤としてのピラゾロ[1,5−a]ピリミジン
EP2402337A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140135319A1 (en) 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
EP2665726A4 (en) 2011-01-21 2014-09-03 Gen Hospital Corp COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES
JP5951750B2 (ja) 2011-04-06 2016-07-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換イミダゾピリジン類およびその中間体
ES2834093T3 (es) 2011-07-21 2021-06-16 Sumitomo Dainippon Pharma Oncology Inc Inhibidores de proteína quinasa heterocíclicos
KR20140077964A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
US9573954B2 (en) 2012-11-16 2017-02-21 University Health Network Pyrazolopyrimidine compounds

Similar Documents

Publication Publication Date Title
JP2015537008A5 (enExample)
JP2014526533A5 (enExample)
JP2011105738A5 (enExample)
JP2015522045A5 (enExample)
JP2013532130A5 (enExample)
JP2016505614A5 (enExample)
JP2011137045A5 (enExample)
JP2016506958A5 (enExample)
JP2012140432A5 (enExample)
JP2012092103A5 (enExample)
JP2017222697A5 (enExample)
RU2020131276A (ru) Терапевтические соединения и композиции
JP2015512883A5 (enExample)
JP2015042636A5 (ja) 有機化合物
JP2012111758A5 (enExample)
JP2017501237A5 (enExample)
JP2011518833A5 (enExample)
JP2013532687A5 (enExample)
JP2017506666A5 (enExample)
JP2017508782A5 (enExample)
JP2018533593A5 (enExample)
JP2020532545A5 (enExample)
JP2017536416A5 (enExample)
JP2015199738A5 (enExample)
JP2013502441A5 (enExample)